This phase 3 trial demonstrated that tebentafusp significantly improved overall survival compared with investigator’s choice in previously untreated HLA-A*02:01-positive metastatic uveal melanoma. The 5-year survival rate doubled with tebentafusp, with durable benefit across all response categories.
Study
|
International, open-label, phase 3 trial [IMCgp100-202; NCT03070392] |
| Previously untreated, HLA-A*02:01-positive pts with unresectable or metastatic uveal melanoma |
| Tebentafusp (n=252) vs investigator’s choice (pembrolizumab, ipilimumab, dacarbazine; n=126)
|
Efficacy
|
ORR: 11% vs 5% (tebentafusp vs. investigators’ choice) |
| Disease control rate: 46% vs 27% |
| mOS: 21.6 mos vs 16.9 mos (HR 0.67 [0.54-0.85]) |
| 5yr OS: 16% vs 8%
|
Safety
|
Not reported in this manuscript
|
Ann Oncol 2026. Published online 2026-05-13
http://doi.org/10.1016/j.annonc.2026.05.695
Reviewed by Ulas D. Bayraktar, MD on Jun 15, 2026
